SCYNEXIS Appoints Dr. Steven K. Burke to Board of Directors

JERSEY CITY, N.J., Sept. 22, 2026 /CourierPR/ -- SCYNEXIS, a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, has announced the appointment of Steven K. Burke, M.D., to its Board of Directors, effective September 18, 2026. Dr. Burke brings more than 30 years of industry experience, with a particular focus on drug development for chronic kidney disease.

Dr. Burke has served as Senior Vice President, Chief Research and Development Officer, and Chief Medical Officer at Akebia Therapeutics, Inc. since 2021. At Akebia, he has overseen the research and development functions, including research, toxicology, pharmacology, clinical operations, data management, biostatistics, clinical research, regulatory affairs, drug safety, and pharmacovigilance. His leadership has been instrumental in the development of Vafseo® (vadadustat) for anemia due to chronic kidney disease and the support of Auryxia® (ferric citrate). Dr. Burke has also played a key role in the development programs for praliciguat and ebribafusp alfa for glomerular diseases and other investigational programs.

Prior to Akebia, Dr. Burke founded Abfero Pharmaceuticals, Inc. and served on its board through its acquisition by Pharmacosmos A/S. He also held the position of Senior Vice President and Chief Medical Officer at Proteon Therapeutics, Inc. from 2006 to 2019, where he contributed to the advancement of several biopharmaceuticals. Dr. Burke received his A.B. from Harvard College and his M.D. from Cornell University Medical School. He completed his residency and fellowship at Brigham and Women’s Hospital and has maintained a Massachusetts medical license since 1989.

SCY-770, a novel and highly selective, direct Adenosine Monophosphate (AMP)-activated protein kinase (AMPK) activator, is being developed as a disease-modifying therapy for ADPKD, a progressive genetic kidney disorder and the leading genetic cause of end-stage renal disease, affecting approximately 140,000 diagnosed patients in the United States. AMPK activation suppresses the mTOR and cAMP signaling pathways that drive cyst cell proliferation and fluid secretion in ADPKD, providing a mechanistically differentiated approach to slowing disease progression. SCY-770 has been evaluated in several Phase 1 trials and one Phase 2a trial in patients with nonalcoholic fatty liver disease (NAFLD). Compelling preclinical pharmacology data supports its potential utility in ADPKD. The Company aims to develop SCY-770 with the goal of reducing cyst growth and disease progression and improving patient quality of life. SCY-770 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ADPKD.

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of ADPKD and has been granted Orphan Drug designation. SCYNEXIS's proprietary antifungal platform "fungerps" includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development.